PDF(Pubmed)
Abstract：
Introduction: The independent diagnostic value of inflammatory markers neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) and the diagnostic efficacy of NLR, derived neutrophil to lymphocyte ratio (dNLR), PLR, and lymphocyte-to-monocyte ratio (LMR) in glioma cases remain unclear. We investigated the correlation of preoperative peripheral blood inflammatory markers with pathological grade, Ki-67 Proliferation Index, and IDH-1 gene phenotype in patients with glioma, focusing on tumor grade and prognosis. Methods: We retrospectively analyzed the clinical, pathological, and laboratory data of 334 patients with glioma with varying grades and 345 with World Health Organization (WHO I) meningioma who underwent initial surgery at the Affiliated Hospital of Jining Medical University from December 2019 to December 2021. The diagnostic value of peripheral blood inflammatory markers for glioma was investigated. Results: The proportion of men smoking and drinking was significantly higher in the glioma group than in the meningioma group (P < .05); in contrast, the age and body mass index (Kg/m2) were significantly lower in the glioma group (P = .01). Significant differences were noted in the pathological grade (WHO II, III, and IV), Ki-67 Proliferation Index, and peripheral blood inflammatory markers such as lymphocyte median, NLR, dNLR, and PLR between the groups (P < .05). No significant correlation existed between peripheral blood inflammatory factors and IDH-1 gene mutation status or tumor location in patients with glioma (P > .05). LMR, NLR, dNLR, and PLR, varied significantly among different glioma types (P < .05). White blood cell (WBC) count, neutrophil, NLR, and dNLR correlated positively with glioma risk. Further, WBC, neutrophil, NLR, dNLR, and LMR had a high diagnostic efficiency. Conclusion: Peripheral blood inflammatory markers, serving as noninvasive biomarkers, offer high sensitivity and specificity for diagnosing glioma, differentiating it from meningioma, diagnosing GBM, and distinguishing GBM from low-grade glioma. These markers may be implemented as routine screening tools.
摘要：
简介:炎性标志物中性粒细胞与淋巴细胞比值(NLR)和血小板与淋巴细胞比值(PLR)的独立诊断价值及NLR的诊断效能,衍生中性粒细胞与淋巴细胞比率(dNLR)，PLR,神经胶质瘤病例中的淋巴细胞与单核细胞比率（LMR）仍不清楚。我们研究了术前外周血炎症标志物与病理分级的相关性。Ki-67增殖指数,胶质瘤患者的IDH-1基因表型，关注肿瘤分级和预后。方法:回顾性分析临床,病态,以及2019年12月至2021年12月在济宁医科大学附属医院接受初次手术的334例不同级别胶质瘤和345例世界卫生组织（WHOI）脑膜瘤患者的实验室数据。探讨外周血炎性标志物对胶质瘤的诊断价值。结果:胶质瘤组男性吸烟和饮酒比例明显高于脑膜瘤组(P<0.05);胶质瘤组的年龄和体重指数(Kg/m2)显著较低(P=0.01)。在病理分级上有显著差异(WHOII，III,andIV),Ki-67增殖指数,和外周血炎症标志物，如淋巴细胞中位数，NLR,dNLR,和PLR组间(P<0.05)。胶质瘤患者外周血炎症因子与IDH-1基因突变状态及肿瘤部位无明显相关性（P>0.05）。LMR,NLR,dNLR,和PLR,不同类型胶质瘤之间差异显著(P<0.05)。白细胞（WBC）计数，中性粒细胞,NLR,dNLR与胶质瘤风险呈正相关。Further,WBC,中性粒细胞,NLR,dNLR,LMR具有较高的诊断效率。结论:外周血炎性标志物,作为非侵入性生物标志物，为诊断神经胶质瘤提供高灵敏度和特异性，将其与脑膜瘤区分开来，诊断GBM，并区分GBM和低级别胶质瘤。这些标记可以作为常规筛选工具来实施。
